검색
ProQR Therapeutics NV
PRQR관심 목록에 추가
1.810USD
+0.060+3.43%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
194.96M시가총액
손실P/E TTM
자세한 내용은 ProQR Therapeutics NV 회사
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV 정보
종목 코드 PRQR
회사 이름ProQR Therapeutics NV
상장일Sep 18, 2014
CEOde Boer (Daniel Anton)
직원 수166
유형Ordinary Share
회계 연도 종료Sep 18
주소Zernikedreef 9
도시LEIDEN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Netherlands
우편 번호2333 CK
전화31881667000
웹사이트https://www.proqr.com/
종목 코드 PRQR
상장일Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
자주 묻는 질문
ProQR Therapeutics NV의 상위 5대 주주는 누구인가요?
ProQR Therapeutics NV의 상위 5대 주주는 다음과 같습니다: Mr. Gerard Platenburg, Ph.D.
ProQR Therapeutics NV(PRQR)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, ProQR Therapeutics NV의 주식을 보유한 기관은 총 122곳이며, 이들이 보유한 주식의 총 가치는 약 38.34M로 전체 발행 주식의 36.39%를 차지합니다. 이는 2025Q4 대비 -5670621.00 증가한 수치입니다.